VKTX - Viking Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

7.15

-0.05 (-0.69%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Triple Moving Average Crossover

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	7.20
Open	7.24
Bid	7.19 x 3100
Ask	7.22 x 800
Day's Range	6.89 - 7.30
52 Week Range	3.26 - 8.87
Volume	1,479,240
Avg. Volume	1,735,682

Market Cap	519.064M
Beta (5Y Monthly)	2.04
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

PR Newswire
Viking Therapeutics to Participate in Upcoming Investor Conferences
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences.
- Ares Management Corporation to Present at the Morgan Stanley Virtual U.S. Financials Conference
  Business Wire
- Clean Harbors to Present at Stifel’s 2020 Virtual Cross Sector Insight Conference
  Business Wire
PR Newswire
Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to its 2020 Annual Meeting of Stockholders. Due to conditions associated with the coronavirus pandemic (COVID-19), including restrictions on in-person gatherings, and in order to support the health and well-being of our stockholders and other meeting participants, Viking's 2020 Annual Meeting of Stockholders will be held in a virtual meeting format only.
PR Newswire
Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2020, after the market close on Thursday, April 30, 2020.
PR Newswire
Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in the Needham & Company 19th Annual Healthcare Conference. The conference, which will take place April 14-15, 2020, is being conducted with a virtual format.
PR Newswire
Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2019, and provided an update on its clinical pipeline and other corporate developments.
PR Newswire
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2019, after the market close on Wednesday, February 26, 2020.
PR Newswire
Viking Therapeutics to Present at Biotech Showcase 2020
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at Biotech Showcase™ 2020, being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.
PR Newswire
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
SAN DIEGO, Nov. 19, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2b clinical trial of VK2809, its novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). Clinical trial sites are open for patient enrollment following clearance of the company's Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA).
PR Newswire
Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 8:30 a.m. ET today - IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH - Clinical Development of VK0214 for X-ALD Expected to Begin 1H20 - Balance ...
PR Newswire
Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019
Conference Call Scheduled for Tuesday, November 5 at 8:30 a.m. Eastern Time SAN DIEGO , Oct. 31, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
PR Newswire
Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
PR Newswire
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 - Continued Progress with VK0214 for ...
PR Newswire
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
Conference Call Scheduled for Thursday, August 1 at 4:30 p.m. Eastern Time SAN DIEGO , July 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
PR Newswire
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
SAN DIEGO, July 2, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Kathy Rouan, Ph.D., to its board of directors. With nearly 30 years of pharmaceutical industry experience, Dr. Rouan provides Viking with drug discovery and development expertise across a broad range of therapeutic areas including gastroenterology, cardiovascular, immune-inflammation and oncology. Dr. Rouan most recently served as senior vice president and head of Projects, Clinical Platforms and Sciences (PCPS) at GlaxoSmithKline (GSK). GSK's PCPS encompasses the company's global clinical operations, statistics and programming, clinical pharmacology, GCP quality, third party resourcing and project management functions and includes approximately 1,800 individuals in 20 countries.